Johnson & Johnson's Q2 2017 earnings call indicates continued strong performance, exceeding analyst estimates.  Management expressed optimism about the second half of the year, citing favorable product launches and easing year-over-year comparisons in several segments.  While some pressure exists in pricing, particularly in certain products like INVOKANA and XARELTO, the overall outlook is positive, especially given the company's robust pipeline and strategic acquisitions.

2
